Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer's disease

Nature Communications

Volumn 5, Issue , 2014, Pages

  Gao, Nan ^a   Sun, Hanjun ^a   Dong, Kai ^a   Ren, Jinsong ^a   Duan, Taicheng ^a   Xu, Can ^a   Qu, Xiaogang ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN INHIBITOR; AMYLOID BETA PROTEIN[1-42]; COBALT; COPPER; CYAN FLUORESCENT PROTEIN; HISTIDINE; IRON; MANGANESE; METAL DERIVATIVE; NICKEL; PEROXIDASE; PROTEIN INHIBITOR; TRANSITION METAL SUBSTITUTED POLYOXOMETALATE DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; POLYOXOMETALATE I; TRANSITION ELEMENT; TUNGSTEN DERIVATIVE;

DISEASE TREATMENT; INHIBITION; NERVOUS SYSTEM DISORDER; PROTEIN; SYMPTOM; TRANSITION ELEMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FLUORESCENCE; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FOLDING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD RETINA BARRIER; CHEMISTRY; IN VITRO STUDY; METABOLISM; SPECTROFLUOROMETRY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-RETINAL BARRIER; IN VITRO TECHNIQUES; MICE; SPECTROMETRY, FLUORESCENCE; TRANSITION ELEMENTS; TUNGSTEN COMPOUNDS;

EID: 84895798299     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4422     Document Type: Article

References (52)

1. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007). (Pubitemid 46432529)
2. Gotz, J. & Ittner, L. M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544 (2008). (Pubitemid 351873467)
3. Geng, J., Li, M., Wu, L., Ren, J. & Qu, X. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment. J. Med. Chem. 55, 9146-9155 (2012).
4. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug. Discov. 4, 307-320 (2005). (Pubitemid 41130944)
5. Orvig, C. & Abrams, M. J. Medicinal inorganic chemistry: introduction. Chem. Rev. 99, 2201-2214 (1999).
6. Barnham, K. J. et al. Platinum-based inhibitors of amyloid-b as therapeutic agents for Alzheimer's disease. Proc. Natl Acad. Sci. USA 105, 6813-6818 (2008). (Pubitemid 351754487)
7. Kim, J. E. & Lee, M. Fullerene inhibits b-amyloid peptide aggregation. Biochem. Biophys. Res. Commun. 303, 576-579 (2003). (Pubitemid 36349209)
8. Prudent, R., Sautel, C. F. & Cochet, C. Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. Biochim. Biophys. Acta 1804, 493-498 (2010).
9. Yanagie, H. et al. Anticancer activity of polyoxomolybdate. Biomed. Pharmacother. 60, 349-352 (2006).
10. Hasenknopf, B. Polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front. Biosci. 10, 275-287 (2005). (Pubitemid 40543034)
11. Rhule, J. T., Hill, C. L., Judd, D. A. & Schinazi, R. F. Polyoxometalates in medicine. Chem. Rev. 98, 327-357 (1998). (Pubitemid 128633433)
12. Judd, D. A. et al. Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J. Am. Chem. Soc. 123, 886-897 (2001). (Pubitemid 32153752)
13. Sarafianos, S. G., Kortz, U., Pope, M. T. & Modak, M. J. Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft. Biochem. J. 319, 619-626 (1996). (Pubitemid 26372225)
14. Seko, A., Yamase, T. & Yamashita, K. Polyoxometalates as effective inhibitors for sialyl-and sulfotransferases. J. Inorg. Biochem. 103, 1061-1066 (2009).
15. Wu, Q., Wang, J., Zhang, L., Hong, A. & Ren, J. Molecular recognition of basic fibroblast growth factor by polyoxometalates. Angew. Chem. Int. Ed. 44, 4048-4052 (2005). (Pubitemid 40886444)
16. Pope, M. T. & Kortz, U. Polyoxometalates. Encyclopedia Inorg. Bioinorg. Chem. 1-14 (2012).
17. Nohra, B. et al. Polyoxometalate-based metal organic frameworks (POMOFs): structural trends, energetics, and high electrocatalytic efficiency for hydrogen evolution reaction. J. Am. Chem. Soc. 133, 13363-13374 (2011).
18. Allain, C. et al. Synthesis, electrochemical and photophysical properties of covalently linked porphyrin-polyoxometalates. Dalton Trans. 42, 2745-2754 (2013).
19. Micoine, K., Hasenknopf, B., Thorimbert, S., Lacote, E. & Malacria, M. Chiral recognition of hybrid metal oxide by peptides. Angew. Chem. Int. Ed. 121, 3518-3520 (2009).
20. Geisberger, G., Paulus, S., Gyenge, E. B., Maake, C. & Patzke, G. R. Targeted delivery of polyoxometalate nanocomposites. Small 7, 2808-2814 (2011).
21. Flutsch, A., Schroeder, T., Grutter, M. G. & Patzke, G. R. HIV-1 protease inhibition potential of functionalized polyoxometalates. Bioorg. Med. Chem. Lett. 21, 1162-1166 (2011).
22. Narasimhan, K. et al. Identification of a polyoxometalate inhibitor of the DNA binding activity of Sox2. ACS Chem. Biol. 6, 573-581 (2011).
23. Geng, J., Li, M., Ren, J., Wang, E. & Qu, X. Polyoxometalates as inhibitors of the aggregation of amyloid b peptides associated with Alzheimer's disease. Angew. Chem. Int. Ed. 50, 4184-4188 (2011).
24. Liu, Z. et al. The use of multifunctional magnetic mesoporous core/shell heteronanostructures in a biomolecule separation system. Biomaterials 32, 4683-4690 (2011).
25. Harney, A. S. et al. Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate. Proc. Natl Acad. Sci. USA 106, 13667-13672 (2009).
26. Haas, K. L. & Franz, K. J. Application of metal coordination chemistry to explore and manipulate cell biology. Chem. Rev. 109, 4921-4960 (2009).
27. Man, B. Y.-W. et al. Group 9 metal-based inhibitors of b-amyloid (1-40) fibrillation as potential therapeutic agents for Alzheimer's disease. Chem. Sci. 2, 917-921 (2011).
28. Pramanik, D., Ghosh, C. & Dey, S. G. Haem-Cu bound Ab peptides: spectroscopic characterization, reactivity, and relevance to Alzheimer's disease. J. Am. Chem. Soc. 133, 15545-15552 (2011).
29. Cassagnes, L. E. et al. The catalytically active copper-amyloid-beta state: coordination site responsible for reactive oxygen species production. Angew. Chem. 125, 11316-11319 (2013).
30. Pedersen, J. T. et al. Rapid exchange of metal between Zn7-metallothionein-3 and amyloid-b peptide promotes amyloid-related structural changes. Biochemistry 51, 1697-1706 (2012).
31. Pirie, C. M., Mey, M. D., Prather, K. L. J. & Ajikumar, P. K. Integrating the protein and metabolic engineering toolkits for next-generation chemical biosynthesis. ACS Chem. Biol. 8, 662-672 (2013).
32. Lyon, D. K. et al. Highly oxidation resistant inorganic-porphyrin analogue polyoxometalate oxidation catalysts. J. Am. Chem. Soc. 113, 7209-7221 (1991).
33. Kim, W. et al. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol. 1, 461-469 (2006).
34. LeVine, III H. T. Thioflavine. Protein Sci. 2, 404-410 (1993).
35. Geng, J., Zhao, C., Ren, J. & Qu, X. Alzheimer's disease amyloid beta converting left-handed Z-DNA back to right-handed B-form. Chem. Commun. 46, 7187-7189 (2010).
36. Yu, H., Ren, J. & Qu, X. Time-dependent DNA condensation induced by amyloid b-peptide. Biophys. J. 92, 185-191 (2007). (Pubitemid 46048426)
37. Co, N. T., Hu, C. K. & Li, M. S. Dual effect of crowders on fibrillation kinetics of polypeptide chains revealed by lattice models. J. Chem. Phys. 138, 185101-185105 (2013).
38. Soto, C. et al. b-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4, 822-826 (1998). (Pubitemid 28331024)
39. Yu, H. et al. Metallosupramolecular complex targeting an a/b discordant stretch of amyloid b peptide. Chem. Sci. 3, 3145-3153 (2012).
40. Yu, H., Ren, J. & Qu, X. Different hydration changes accompanying copper and zinc binding to amyloid b-peptide: water contribution to metal binding. Chem. Bio. Chem. 9, 879-882 (2008).
41. Walsh, D. M. & Teplow, D. B. Alzheimer's disease and the amyloid b-protein. Prog. Mol. Biol. Transl. Sci. 107, 101-124 (2012).
42. Geng, J., Li, M., Wu, L., Chen, C. & Qu, X. Mesoporous silica nanoparticlebased H2O2 responsive controlled-release system used for Alzheimer's disease treatment. Adv. Healthc Mater. 1, 332-336 (2012).
43. Giuffrida, M. L. et al. b-amyloid monomers are neuroprotective. J. Neurosci. 29, 10582-10587 (2009).
44. Unal, B. et al. L-histidine coated iron oxide nanoparticles: synthesis, structural and conductivity characterization. J. Alloy. Compd 505, 172-178 (2010).
45. Ipe, B. I., Yoosaf, K. & Thomas, K. G. Functionalized gold nanoparticles as phosphorescent nanomaterials and sensors. J. Am. Chem. Soc. 128, 1907-1913 (2006). (Pubitemid 43277331)
46. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
47. Zawisza, I., Rozga, M. & Bal, W. Affinity of copper and zinc ions to proteins and peptides related to neurodegenerative conditions (Ab, APP, a-synuclein, PrP). Coordin. Chem. Rev. 256, 2297-2307 (2012).
48. Zhou, Y. et al. Inhibition of amyloid-b protein fibrillization upon interaction with polyoxometalates nanoclusters. Colloids and Surfaces A: Physicochem. Eng. Aspects 375, 97-101 (2011).
49. Stroobants, K. et al. Polyoxometalates as a novel class of artificial proteases: selective hydrolysis of lysozyme under physiological pH and temperature promoted by a cerium(IV) Keggin-type polyoxometalate. Chem. Eur. J. 19, 2848-2858 (2013).
50. Cabaleiro-Lago, C. et al. Inhibition of amyloid b protein fibrillation by polymeric nanoparticles. J. Am. Chem. Soc. 130, 15437-15443 (2008).
51. Pardridge, W. M. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimer's Dement 5, 427-432 (2009).
52. Lee, J. et al. On-demand drug release system for in vivo cancer treatment through self-assembled magnetic nanoparticles. Angew. Chem. Int. Ed. 125, 4480-4484 (2013).